ARCHIVES

FDA Says ImClone Data Insufficient To Evaluate Colorectal Cancer Drug C225.

This article is from The Cancer Letter archive.

Vol. 28 No. | March 8, 2002

Download PDF Visit The Full Archive

Related Articles

DCT Board Okays $3 Million In New Programs, $8 Million In Recompetitions

October 24, 1980

Totality Of Evidence Causes Concern About New Findings.

December 7, 2007

Tobacco Regulation: ACS Advocates Giving FDA Full Authority Over Tobacco

January 23, 1998

NCI Cooperative Group, Cancer Center Trials Listed

May 30, 2008

NCI’s Rosenberg Confirms 2002 Immunotherapy Results

April 29, 2005

In Brief: Ways & Means Shakeup Means More Liberal Health Insurance Bill; OMB’s Nutty Rational For Cuts

December 20, 1974